Crispr Therapeutics' current revenue from CASGEVY is limited by high costs, profit-sharing, and logistical hurdles. Click ...

In a ground-breaking first for South Africa and the African continent, local patients are participating in a pioneering international gene-editing clinical trial that may revolutionise treatment for ...

In a global first for Africa, UCT is participating in a clinical trial to reprogramme genes and halt hereditary angioedema.

Crispr Therapeutics AG leverages CASGEVY's rollout, a robust pipeline in cardiovascular, oncology, & partnerships to large ...

SNIPR Biome ApS ("SNIPR”), the company pioneering the development of precision medicines using CRISPR technology for microbial gene therapy, today announced that the first patient has been dosed in ...

Although our cellular clocks differ dramatically, scientists argue that human aging is one of the highest risk factors for a ...

GenEditBio has dosed the first subject in an investigator-initiated trial of its in vivo genome editing programme, GEB-101, ...

The Conference Forum announced the first keynotes of the DPHARM®: Disruptive Innovations to Modernize Clinical Research conference, including the ...

TGFBI corneal dystrophy is a group of genetic eye disorders caused by mutations in the TGFBI gene, resulting in abnormal ...

"My friends and peers are rushing to finish experiments because they are afraid their funding will disappear ... (and) are ...